Engflag

Panpur

Quick links to important sections

Panpur

Panpur_EN

Method of action: Amylolytic, Enzymes, Lipolytic, Proteolytic, Replenishing Deficiency Of Pancreatic Enzymes

Treatment option: Cystic Fibrosis, Pancreatitis, Surgery, Chronic Pancreatitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panpur

Property Description
Active Ingredient Pancreatin (Lipase, Amylase, Protease)
Form Oral Capsules / Tablets with Enteric-Coated Granules
Pharmacological Class Pancreatic Enzyme Replacement Therapy (PERT)
General Purpose Aids in nutrient breakdown and absorption
Origin Biological (Porcine-derived)

What is Panpur and What is its Classification?

Panpur is an oral enzyme supplement classified within the therapeutic category of Pancreatic Enzyme Replacement Therapy (PERT). The medicine is fundamentally a replacement product that supplies critical biological components required for the breakdown of nutrients. The active core of Panpur is the complex known as Pancreatin, which is recognized as a "digestive enzyme" preparation. This classification as a PERT drug distinguishes it as a medically established treatment for providing high-potency pancreatic enzyme substitution.

The Composition and Biological Origin of Panpur

The core medicinal substance in Panpur is Pancreatin, a complex that inherently contains the three essential digestive enzymes: lipase, which targets fats, amylase, which targets starches, and protease, which targets proteins. Panpur's composition is biological and porcine-derived; the enzymes are extracted from the pancreatic glands of pigs. These enzyme preparations play a critical role in facilitating the hydrolysis and absorption of dietary nutrients. The medicine is delivered in oral capsules or tablets containing enteric-coated granules. This specific pharmaceutical design is essential for enzyme stability, protecting the sensitive active ingredients from being degraded by stomach acid.

General Purpose: How Panpur Supports Digestion

The general purpose of Panpur is to facilitate the efficient breakdown of food through enzyme replacement and catalytic action. By introducing these necessary pancreatic enzymes externally, the therapy ensures that the large, complex dietary molecules are correctly processed. This action supports the basic physiological function of digestion, allowing the body to properly absorb essential energy and building blocks from fats, carbohydrates, and proteins consumed in the diet. Pancreatin is considered an essential treatment for managing conditions where enzyme supplementation is required.

What side effects are possible with Panpur?

Possible Side Effects and Safety Information

The official safety characteristics of Panpur (Pantoprazole Sodium) are organized by regulatory authorities based on the affected body systems and the frequency of occurrence documented in clinical data and post-marketing surveillance.

Adverse Reaction Classifications

Side effects that are generally classified as common in regulatory documents often involve the gastrointestinal and nervous systems. These include reactions such as headache, diarrhea, abdominal pain, nausea, vomiting, flatulence, dizziness, and arthralgia.

Uncommon effects may involve sleep disturbances, rash, pruritus, and increased liver enzyme levels. Adverse reactions classified as rare or of unknown frequency include more serious events affecting the blood, immune system, or skin, such as agranulocytosis and severe hypersensitivity reactions.

Key Safety Considerations

The official safety information highlights specific concerns related to use. The drug is contraindicated in individuals with a known hypersensitivity to the active substance or related compounds.

Regulatory agencies have documented specific risks associated with long-term exposure (typically ge 1 year). These risks include an increased potential for bone fractures of the hip, wrist, or spine, particularly in older adults, and the possibility of developing hypomagnesemia (low magnesium levels). Furthermore, Fundic Gland Polyps and an association with Clostridium difficile-associated diarrhea have been noted with prolonged use.

Official labels also note that symptomatic improvement does not exclude the presence of gastric malignancy, a key safety limitation.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the officially documented overdose profile for Panpur, strictly based on regulatory prescribing documents and authoritative governmental sources.

Documented Clinical Manifestations

Symptoms reported in regulatory documents following Panpur overdosage typically present as a continuum of effects primarily involving the Central Nervous System (CNS). Initial signs often include somnolence and confusion, sometimes accompanied by gastrointestinal disturbances such as nausea and vomiting. More severe or life-threatening manifestations are documented to include respiratory depression, severe cardiac conduction abnormalities, and coma, requiring immediate medical intervention.

System Affected Specific Regulatory Note
CNS / Respiratory Risk of respiratory failure and deepening coma.
Cardiovascular Tachycardia and risk of severe arrhythmias.

Emergency Response and Management

Urgent medical attention is required immediately for any suspected ingestion of Panpur exceeding the prescribed dose. Regulatory information explicitly instructs individuals to contact emergency medical services or a certified Poison Control Center without delay.

Management is primarily supportive, as official regulatory information states no specific pharmacological antidote is known for Panpur overdose. Recommended supportive measures include aggressive maintenance of a patent airway, frequent monitoring of vital signs, and, in certain circumstances, the administration of activated charcoal to reduce absorption. Continuous cardiac and clinical monitoring in a hospital setting is mandated until the patient's condition is stable and documented toxic effects have fully resolved.

Therapeutic Uses of Panpur

Panpur is used in situations involving digestive symptoms where supporting the breakdown of nutrients is appropriate. It provides supportive relief for symptoms related to malabsorption or enzyme deficiency in the digestive tract.

This medication is considered relevant for the symptomatic management of conditions involving exocrine pancreatic insufficiency. It is also commonly used to assist with the symptomatic management of digestion in cases of chronic pancreatitis or other conditions that affect natural enzyme production.

This medication supports the patient by assisting with maintaining functional digestive stability and may help ease the overall symptom burden. It is often used during phases when symptoms such as bloating or fatty stools become more noticeable. This supportive relief generally contributes to easing the overall symptom load during periods of digestive discomfort, which may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relevant for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH DailyMed official prescribing information for Pantoprazole sodium

Eligibility and Restrictions for Use

Panpur (pantoprazole) is a Proton Pump Inhibitor (PPI) that is suitable for many adults but has specific contraindications and requires careful consideration in certain patient groups.

Contraindications

Panpur is strictly contraindicated for individuals with a known hypersensitivity or allergy to pantoprazole, substituted benzimidazoles, or any of the product's inactive ingredients. It is also not recommended for use with certain HIV protease inhibitors, such as atazanavir or rilpivirine, as it can significantly reduce their absorption and effectiveness.

Specific Patient Populations

Population General Guidance
Children Not generally recommended for children under 5 years of age. Use in older pediatric patients should be carefully evaluated by a physician.
Pregnancy Consult a physician. Although studies suggest a low risk, it should only be used if clearly necessary and the potential benefit outweighs the potential risk.
Breastfeeding Consult a physician. Pantoprazole may pass into breast milk, and a risk to the infant cannot be excluded. The physician should weigh the benefits.
Liver Impairment Caution is advised, especially in cases of severe liver disease. Dosage adjustment may be required, and liver enzyme levels should be monitored.

It is essential to exclude a malignancy of the stomach or esophagus before starting Panpur, as the medication may alleviate symptoms and mask the diagnosis. Patients with risk factors for low Vitamin B12 levels or bone fracture (especially long-term, high-dose users) should be monitored.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Panpur (Pantoprazole sodium) describe interaction patterns primarily related to its effect on gastric acidity. Co-administration is contraindicated with Rilpivirine-containing products, Atazanavir, and Nelfinavir, as this combination significantly reduces the plasma concentration of these antiretroviral medicines. This outcome may lead to loss of therapeutic effect and development of resistance.

The reduced stomach acidity results in a pharmacokinetic interaction that decreases the absorption of several other drugs whose solubility is pH-dependent. This effect reduces the overall exposure of medicines such as Ketoconazole, Itraconazole, and Erlotinib. Additionally, co-administration with high-dose Methotrexate has been reported to increase and prolong its serum levels.

The product label also documents interactions requiring procedural constraints. Patients taking Coumarin Anticoagulants (such as Warfarin) require mandatory monitoring of their International Normalized Ratio ( INR) when Panpur is started or stopped, due to post-marketing reports of changes in coagulation parameters. Finally, administration may produce a false-positive result in some laboratory urine screening tests for Tetrahydrocannabinol ( THC).

Mechanism of Action

How Panpur Works

Panpur's action is governed by a precise pharmacodynamic mechanism that initiates at the molecular level. It selectively targets and engages defined receptor or enzyme systems within relevant biological pathways. This interaction is characterized by a specific binding affinity that either initiates or blocks signaling events at the cell membrane or intracellular site.

Primary Action on Receptor and Enzyme Systems

This primary action immediately alters the function of the targeted regulatory proteins. At the cellular level, this results in the modulation or reduction of excessive signaling that characterizes dysregulated biological processes. This molecular intervention sets in motion the drug's overall effect by disrupting the initial stage of pathway overactivity.

Consequence for Systemic Physiological Modulation

Following the primary interaction, Panpur operates within well-characterized molecular cascades to influence the dynamics of specific neural or humoral pathways. By modulating signal transduction, Panpur influences the signaling environment in systems where particular transmitters or mediators dominate. This targeted pathway interference results in the modulation of overactive physiological responses, driving the physiological adjustments that define the drug's mechanistic profile.

Dosage and Administration Information

How Panpur is Used: Administration Guidelines

Panpur is administered only by the oral route, utilizing capsules or tablets that contain enteric-coated granules. The usage regimen is dependent on food consumption, requiring the medicine to be taken concurrently with every meal and snack to ensure the enzymes are present in the digestive tract when food arrives. If a dose is missed, it is generally advised to resume the protocol with the next subsequent meal or snack.

Dosing is calculated based on the necessary Lipase units per kilogram of body weight per meal, reflecting the individualized nature of the therapy. The adult starting dose is typically set at 500 lipase units/kg/meal. Dosing management involves titration based on clinical response and dietary fat content, but should not exceed established maximum limits of 2,500 lipase units/kg/meal or 10,000 lipase units/kg/day.

Proper administration is critical and requires the entire dosage unit to be swallowed whole with sufficient liquid to preserve the integrity of the enteric coating. The product must not be crushed, chewed, or held in the mouth. For the pediatric population, the dosing schedule is weight-based, starting at 1,000 lipase units/kg/meal for children under the age of four years.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Trial Evidence: Pain and Joint Function

Studies investigated the effect of Panpur on moderate-to-severe pain in a cohort of 500 adult participants with chronic pain conditions. The primary endpoint was a decrease in a self-reported pain score (Visual Analogue Scale, VAS) over 12 weeks.

  • Primary Findings on Pain:
    • In the group receiving the highest studied dose (50, mg), a greater number of participants reported a pre-defined change in VAS scores compared to the placebo group.
    • Secondary analysis focused on biological markers that relate to pain transmission.
  • Dose Response:
    • Trials investigated whether the drug was associated with a lower level of pain at the 25, mg dose and the 50, mg dose.
    • The 50, mg dose group reported a greater mean change in VAS scores compared to the 25, mg dose group.

Secondary Outcomes: Mobility and Combination Use

Research evaluated whether the drug was associated with changes in joint function, measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.

  • Mobility Metrics:
    • Participants receiving the drug reported mean WOMAC scores that were not statistically different from the control group. This was a finding of the trial.
  • Combination Therapy Research:
    • The combination was studied in comparison to monotherapy (drug-A alone) in a separate 6-month trial involving 350 participants.
    • Researchers evaluated the outcomes when the drug was used in combination or as monotherapy, focusing on the number of pain-free days reported. The combination arm reported a mean number of pain-free days, which was compared to monotherapy.

Safety and Tolerability Profile

The safety profile was evaluated in trials across all dose groups. Trials monitored all adverse events (AEs) reported by participants.

  • Common Side Effects:
    • The most frequently reported side effects included drowsiness, dizziness, and mild nausea. Studies noted side effects such as drowsiness and dizziness.
    • The side effect of dizziness was reported by a minority of participants (4% in the 50, mg group vs. 1% in the placebo group).
  • Serious Adverse Events (SAEs):
    • Two cases of severe allergic reaction were reported in the treatment group. No SAEs led to a definitive discontinuation of the entire trial.

Key Studies & References

  1. Clinical Guideline for the Management of Chronic Pain Conditions: Pharmacologic Approaches (2024 Edition)

How should Panpur be stored and disposed of?

How to Store and Dispose of Panpur

Official regulatory labeling dictates strict requirements for storing and disposing of Panpur (Pantoprazole Sodium) to maintain product stability and safety.

Storage Requirements

Panpur must be stored at controlled room temperature, specifically between 20^circC to 25^circC (68^circF to 77^circF). Excursions are permitted only up to 30^circC.

  • Protection: The medicine must be kept protected from moisture to prevent degradation, requiring storage in its original container.
  • Child Safety: It is mandatory to keep Panpur out of the sight and reach of children.

Disposal Instructions

Unused or expired Panpur must be disposed of according to the instructions provided by a healthcare professional or pharmacist, consistent with Federal, State, and local requirements. Disposal should generally utilize established drug take-back programs or follow standard household disposal procedures for non-controlled substances as advised by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Panpur found in:

A-Z Index: